EPCAM and fatty liver disease: The aim of this study is to investigate the molecular components of the signaling pathways that are responsible for the development and progression of HCC and to provide the evidence for the clinical activity of FGF19, FGFR4, and EpCAM in patients with HCC arising from fatty liver disease.